Oncology Research and Treatment

 

Effektivität intramuskulär verabreichten Cytosin-Arabinosids bei der ambulanten Behandlung von Kindern mit akuter Leukämie in Remission

Intramuskuläre Gabe von ARA-C

Haas R.J. · Helmig M. · Prentl E.

Author affiliations

Abteilung für Hämatologie und Onkologie der Universitäts-Kinderklinik im Dr. von Haunerschen Kinderspital (Direktor: Prof. K. Betke), München Effect on Peripheral Blood Cells in Children with Acute Leukemia During Remission by Intramuscular Injection of Arabinosyl-Cytosine

Related Articles for ""

Onkologie 1980;3:53–57

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: April 17, 2009
Issue release date: 1980

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)

For additional information: https://www.karger.com/ORT

Abstract

Anhand peripherer Blutbildparameter bei Patienten mit akuter Leukämie in hämatologischer Vollremission wurde überprüft, ob Cytosin-Arabinosid (Ara-C) – ambulant intramuskulär im Abstand von 12 h gegeben – eine gleichwertige biologische Effektivität erbringt wie bei der üblichen stationären kontinuierlichen intravenösen Infusion. Jeder Therapiezyklus dauerte 5 Tage. Ausgewertet wurden 129 Zyklen nach intramuskulärer Gabe und 11 Zyklen nach intravenöser Gabe. Die Dosis des Ara-C wurde bei der intramuskulären gegenüber der intravenösen Gabe um 20 % erhöht. Die Überprüfung erfolgte retrospektiv mittels des Friedmann-Tests. Es ergab sich ein signifikanter Abfall sämtlicher Parameter des peripheren Blutes nach intramuskulärer Gabe. Bei Erstzyklen war die Depression der Blutbildwerte bis zu 3 Wochen bei Mehrfachzyklen nur bis zu 2 Wochen nach Applikation von Ara-C nachweisbar. Wurden die Wirkungen von Ara-C nach intravenöser Gabe mit denen nach intramuskulärer Gabe verglichen, ergaben sich beinahe identische Veränderungen der peripheren Blutbildparameter. Lokale Reaktionen nach intramuskulärer Gabe von Ara-C traten nicht auf.

© 1980 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: April 17, 2009
Issue release date: 1980

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)

For additional information: https://www.karger.com/ORT


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP